Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

Inclusion Criteria:

Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation (phase 1b must be either Non-Small Cell Lung Cancer or Colorectal Cancer)
Unresectable or metastatic disease
No available treatment with curative intent
Adequate organ function

Exclusion Criteria:

History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow
Other active cancer
Cardiac abnormalities